Induct (INDCT) Company presentation summary
Event summary combining transcript, slides, and related documents.
Company presentation summary
11 Aug, 2026Vision and strategic direction
Aims to become the global operating system for care pathways, enhancing healthcare outcomes through connected workflows and data-driven care.
Focused on a clear strategic direction with a reset organization and a healthy balance sheet.
Roadmap targets higher ARR and international expansion, leveraging highly scalable technologies.
Core products and business model
Offers SaaS solutions for care pathways, grant finders, and innovation management, all on annual subscription models with consulting revenues.
Care pathway technology is validated, scalable across diseases and geographies, and deployed in NHS England for severe asthma.
Grant platforms and innovation management solutions support public sector and healthcare organizations, delivering measurable customer value.
Market opportunity and growth
Operates in the fast-growing care management and healthcare SaaS market, with the care orchestration category projected to exceed $60B within a decade.
Growth driven by regulatory mandates, cost savings, and a CAGR above 15% in the sector.
Targets vertical market dominance in UK respiratory diseases, with expansion into Northern Europe and additional care pathways.
Latest events from Induct
- Positive EBITDA and strong margins achieved amid lower revenues; NOK 15m rights issue completed.INDCT
Q2 2026 - EBITDA returned to positive territory as restructuring took effect, despite lower revenues.INDCT
Q1 2026 - EBITDA swung to 7.5 MNOK, equity ratio hit 74%, and net debt dropped to 12 MNOK.INDCT
Q4 2025 - EBITDA doubled and equity ratio neared 79% as margins improved despite lower revenue.INDCT
Q3 2025 - EBITDA down 10% year-over-year; capital raised and UK expansion plans underway.INDCT
Q2 2025 - Revenue and EBITDA fell in Q3, but cost cuts and new markets aim to restore growth.INDCT
Q3 2024 - EBITDA more than doubled despite lower revenues, driven by efficiency and cost reductions.INDCT
Q2 2024 - EBITDA up 25% and net loss sharply reduced, driven by cost cuts and strategic expansion.INDCT
Q1 2025 - Collaboration accelerates high-margin asthma care scaling and global expansion with new pathways.INDCT
Investor Update